BioLineRx Ltd. (NASDAQ:BLRX – Get Rating) – Equities researchers at HC Wainwright upped their FY2022 earnings per share estimates for BioLineRx in a note issued to investors on Tuesday, November 15th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of ($0.56) for the year, up from their prior forecast of ($0.58). The consensus estimate for BioLineRx’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for BioLineRx’s Q4 2022 earnings at ($0.15) EPS and FY2023 earnings at ($0.62) EPS.
BioLineRx (NASDAQ:BLRX – Get Rating) last announced its quarterly earnings data on Tuesday, August 16th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02).
BioLineRx Stock Up 1.6 %
Shares of NASDAQ BLRX opened at $0.68 on Friday. The stock has a market capitalization of $41.84 million, a P/E ratio of -1.39 and a beta of 1.86. BioLineRx has a one year low of $0.57 and a one year high of $3.02. The firm’s 50 day simple moving average is $0.92 and its two-hundred day simple moving average is $1.25. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.12 and a quick ratio of 4.58.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in BLRX. Geneos Wealth Management Inc. raised its stake in BioLineRx by 25.8% during the second quarter. Geneos Wealth Management Inc. now owns 41,450 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 8,500 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of BioLineRx by 49.1% in the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 22,478 shares during the last quarter. Virtu Financial LLC boosted its stake in BioLineRx by 195.6% in the 3rd quarter. Virtu Financial LLC now owns 46,168 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 30,551 shares in the last quarter. PVG Asset Management Corp purchased a new stake in BioLineRx during the 3rd quarter valued at about $44,000. Finally, Apollon Wealth Management LLC bought a new stake in BioLineRx during the 3rd quarter valued at about $45,000. Institutional investors own 2.22% of the company’s stock.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- Get a free copy of the StockNews.com research report on BioLineRx (BLRX)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.